Naltrexone
- Generic Name
- Naltrexone
- Brand Names
- Contrave, Embeda, Vivitrol
- Drug Type
- Small Molecule
- Chemical Formula
- C20H23NO4
- CAS Number
- 16590-41-3
- Unique Ingredient Identifier
- 5S6W795CQM
- Background
Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.
- Indication
Used as an adjunct to a medically supervised behaviour modification program in the maintenance of opiate cessation in individuals who were formerly physically dependent on opiates and who have successfully undergone detoxification. Also used for the management of alcohol dependence in conjunction with a behavioural modification program.
- Associated Conditions
- Alcohol Dependency, Cholestatic pruritus, Obesity, Opioid Dependence, Severe Pain
- Associated Therapies
- -
Low-dose Naltrexone for Bladder Pain Syndrome
- Conditions
- Interventions
- First Posted Date
- 2020-06-29
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 40
- Registration Number
- NCT04450316
- Locations
- 🇺🇸
Stanford Health Care, Stanford, California, United States
Effect of Naltrexone in Achieving and Maintaining Abstinence From Alcohol in Patients With Cirrhosis.
- Conditions
- Interventions
- First Posted Date
- 2020-05-18
- Last Posted Date
- 2023-03-28
- Lead Sponsor
- Institute of Liver and Biliary Sciences, India
- Target Recruit Count
- 100
- Registration Number
- NCT04391764
- Locations
- 🇮🇳
Institute of Liver and Biliary Sciences, New Delhi, Delhi, India
Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19
- Conditions
- Interventions
- First Posted Date
- 2020-04-28
- Last Posted Date
- 2022-01-26
- Lead Sponsor
- William Beaumont Hospitals
- Target Recruit Count
- 70
- Registration Number
- NCT04365985
- Locations
- 🇺🇸
William Beaumont Hospital, Royal Oak, Michigan, United States
Treatment of Chronic Itch in Atopic Dermatitis With Opioid Antagonist Naltrexone
- Conditions
- Interventions
- First Posted Date
- 2020-03-30
- Last Posted Date
- 2023-04-04
- Lead Sponsor
- University of Minnesota
- Registration Number
- NCT04325802
- Locations
- 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
Rapid Antidepressant Improvement Secondary to Excitatory Brain Responses
- First Posted Date
- 2020-02-19
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Marta Peciña, MD PhD
- Target Recruit Count
- 120
- Registration Number
- NCT04276259
- Locations
- 🇺🇸
Bellefield Tower, Pittsburgh, Pennsylvania, United States
A Novel Human Lab Model for Screening AUD Medications
- Conditions
- Interventions
- First Posted Date
- 2020-01-31
- Last Posted Date
- 2023-09-14
- Lead Sponsor
- University of California, Los Angeles
- Target Recruit Count
- 53
- Registration Number
- NCT04249882
- Locations
- 🇺🇸
UCLA Addictions Lab, Los Angeles, California, United States
Opioids and Social Support Enhanced Extinction Effects
- First Posted Date
- 2019-11-18
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- University of California, Los Angeles
- Target Recruit Count
- 60
- Registration Number
- NCT04166071
- Locations
- 🇺🇸
UCLA Department of Psychology, 5514 Pritzker Hall, Los Angeles, California, United States
🇺🇸UCLA, Los Angeles, California, United States
Treatment of Chronic Itch in Atopic Dermatitis With Topical Naltrexone
- Conditions
- Interventions
- First Posted Date
- 2019-11-06
- Last Posted Date
- 2021-04-20
- Lead Sponsor
- University of Minnesota
- Registration Number
- NCT04154033
- Locations
- 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States
Low Dose Naltrexone for Chronic Pain in Osteoarthritis and Inflammatory Arthritis
- Conditions
- Interventions
- First Posted Date
- 2019-10-03
- Last Posted Date
- 2020-01-09
- Lead Sponsor
- Brigham and Women's Hospital
- Registration Number
- NCT04115020
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Low-Dose Naltrexone in Combination With Standard Treatment in Women With Endometriosis
- Conditions
- Interventions
- First Posted Date
- 2019-05-31
- Last Posted Date
- 2022-11-03
- Lead Sponsor
- Milton S. Hershey Medical Center
- Target Recruit Count
- 9
- Registration Number
- NCT03970330
- Locations
- 🇺🇸
Penn State Hershey Medical Center, Hershey, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.